In this installment of Elizabeth Holmes' sworn SEC deposition (recorded July 13, 2017), the Theranos founder faces intense questioning regarding the company’s high-stakes retail partnerships with Walgreens and Safeway. Investigators probe Holmes on: The Walgreens Partnership & Test Menu (2012–2014): Scrutiny over Theranos’s promised 600-test menu, whether proprietary TSPU / "miniLab" devices or modified third-party commercial analyzers were actually running tests, and throughput bottlenecks. Deleted Demo Results: Emails revealing failed out-of-range results (such as Vitamin D, calcium, and thyroid markers) being deleted from demonstration reports shown to Walgreens executives prior to commercial launch. Master Service Agreements & Innovation Fees: The contractual reality behind the $100M+ "innovation fee," equity conversion options, exclusivity agreements, and whether Walgreens ever had a binding commitment to a national rollout. Trouble Behind the Scenes: Internal texts and emails between Elizabeth Holmes and Ramesh "Sunny" Balwani showing growing friction, missed IT integration deadlines, low patient volume, high venipuncture draw rates vs. promised fingersticks, and shifting toward a "rental agreement" model. The Collapsing Safeway Deal: Negotiations surrounding wellness centers, failed pilot programs, disputes over exclusivity, and why Theranos never actually launched in Safeway stores. Listen To Hidden Killers Podcast ANYWHERE! Listen Here: https://linktr.ee/hiddenkillers Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.